Persistence of Antibody Response to N. Meningitidis Group C in Children

A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00316654

Enrollment

489

Registered

2006-04-21

Start date

2005-02-28

Completion date

2005-10-31

Last updated

2017-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of Meningococcal Infection

Keywords

Prevention of Meningococcal Meningitis, vaccines, conjugate, immunology, child, antibody persistence

Brief summary

Persistence of Antibody Response to N. meningitidis Group C in Children

Interventions

BIOLOGICALMeningococcal C conjugate vaccine

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

7 Months to No maximum

Healthy volunteers

Yes

Inclusion criteria

* healthy children

Exclusion criteria

* previous ascertained or suspected disease caused by N. meningitidis * previous significant acute or chronic infections * any other serious disease

Design outcomes

Primary

Measure	Time frame
Immunogenicity: serum antibody responses, as measured by bactericidal activity,using hBCA	—

Secondary

Measure	Time frame
Evaluate and compare persistence of antibody response to N. meningitidis serogroup C as measured by serum bactericidal activity	—
safety and tolerability	—

Countries

Poland, Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026